Mark S. Shearman - 22 Dec 2021 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, Chief Scientific Officer
Signature
/s/ Mark S. Shearman
Issuer symbol
EDIT
Transactions as of
22 Dec 2021
Net transactions value
$0
Form type
4
Filing time
23 Dec 2021, 15:10:36 UTC
Previous filing
16 Jun 2021
Next filing
11 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +9,084 +28% $0.000000 41,785 22 Dec 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 14, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 14, 2022, subject to continued service.